Gut microbiota in COVID-19: new insights from inside

References

• Coronavirus Resource Center, Johns Hopkins University & Medicine. COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html.
   Google Scholar
• Zuo T, Zhang F, Lui G, Yeoh YK, Li A, Zhan H, Wan Y, Chung A, Cheung CP, Chen N, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159:944–955.e8. doi:10.1053/j.gastro.2020.05.048.
   PubMed Web of Science ®Google Scholar
• Albrich WC, Ghosh TS, Ahearn-Ford S, Mikaeloff F, Lunjani N, Forde B, Suh N, Kleger G-R, Pietsch U, Frischknecht M, et al. A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2. Gut Microbes. 2022;14(1):2073131. doi:10.1080/19490976.2022.2073131.
   PubMed Web of Science ®Google Scholar
• Bowerman KL, Rehman SF, Vaughan A, Lachner N, Budden KF, Kim RY, Wood D, Gellatly SL, Shukla SD, Wood LG, et al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun. 2020;11:5886. doi:10.1038/s41467-020-19701-0.
   PubMed Web of Science ®Google Scholar
• Barcik W, Boutin R, Sokolowska M, Finlay BB. The role of lung and gut microbiota in the pathology of Asthma. Immunity. 2020;52:241–26. doi:10.1016/j.immuni.2020.01.007.
   PubMed Web of Science ®Google Scholar
• Wypych TP, Pattaroni C, Perdijk O, Yap C, Trompette A, Anderson D, Creek DJ, Harris NL, Marsland BJ. Microbial metabolism of L-tyrosine protects against allergic airway inflammation. Nat Immunol. 2021;22:279–286. doi:10.1038/s41590-020-00856-3.
   PubMed Web of Science ®Google Scholar
• Antunes KH, Fachi JL, de Paula R, da Silva EF, Pral LP, Dos SAÁ, Dias G, Vargas JE, Puga R, Mayer FQ, et al. Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response. Nat Commun. 2019;10:3273. doi:10.1038/s41467-019-11152-6.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Anto JM, Czarlewski W, Haahtela T, Fonseca SC, Iaccarino G, Blain H, Vidal A, Sheikh A, Akdis CA, et al. Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. Allergy. 2021;76:735–750. doi:10.1111/all.14549.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Castrellón P, Gandara-Martí T, Abreu Y, AT A, CD NR, López-Orduña E, Jiménez-Escobar I, Jiménez-Gutiérrez C, López-Velazquez G, Espadaler-Mazo J. Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. 2022;14:2018899. doi:10.1080/19490976.2021.2018899.
   PubMed Web of Science ®Google Scholar
• Biliński J, Winter K, Jasiński M, Szczęś A, Bilinska N, Mullish BH, Małecka-Panas E, Basak GW. Rapid resolution of COVID-19 after faecal microbiota transplantation. Gut. 2022;71:230–232. doi:10.1136/gutjnl-2021-325010.
   PubMed Web of Science ®Google Scholar
• Chen Z, Lv Y, Xu H, Deng L. Herbal medicine, gut microbiota, and COVID-19. Front Pharmacol. 2021;12:646560. doi:10.3389/fphar.2021.646560.
   PubMedGoogle Scholar
• Nagata N, Takeuchi T, Masuoka H, Aoki R, Ishikane M, Iwamoto N, Sugiyama M, Suda W, Nakanishi Y, Terada-Hirashima J, et al. Human gut microbiota and its metabolites impact immune responses in COVID-19 and its complications. Gastroenterology. 2022;164:272–288. doi:10.1053/j.gastro.2022.09.024.
   PubMed Web of Science ®Google Scholar
• Tang L, Gu S, Gong Y, Li B, Lu H, Li Q, Zhang R, Gao X, Wu Z, Zhang J, et al. Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity. Engineering (Beijing). 2020;6:1178–1184. doi:10.1016/j.eng.2020.05.013.
   PubMedGoogle Scholar
• Zuo T, Zhan H, Zhang F, Liu Q, Tso E, Lui G, Chen N, Li A, Lu W, Chan F, et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge. Gastroenterology. 2020;159:1302–1310.e5. doi:10.1053/j.gastro.2020.06.048.
   PubMed Web of Science ®Google Scholar
• Cao J, Wang C, Zhang Y, Lei G, Xu K, Zhao N, Lu J, Meng F, Yu L, Yan J, et al. Integrated gut virome and bacteriome dynamics in COVID-19 patients. Gut Microbes. 2021;13:1–21. doi:10.1080/19490976.2021.1887722.
   PubMed Web of Science ®Google Scholar
• Lv L, Gu S, Jiang H, Yan R, Chen Y, Chen Y, Luo R, Huang C, Lu H, Zheng B, et al. Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features. Commun Biol. 2021;4:480. doi:10.1038/s42003-021-02036-x.
   PubMed Web of Science ®Google Scholar
• Xu R, Liu P, Zhang T, Wu Q, Zeng M, Ma Y, Jin X, Xu J, Zhang Z, Zhang C. Progressive deterioration of the upper respiratory tract and the gut microbiomes in children during the early infection stages of COVID-19. J Genet Genomics. 2021;48:803–814. doi:10.1016/j.jgg.2021.05.004.
   PubMed Web of Science ®Google Scholar
• Wu Y, Cheng X, Jiang G, Tang H, Ming S, Tang L, Lu J, Guo C, Shan H, Huang X. Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization. NPJ Biofilms Microbiomes. 2021;7:61. doi:10.1038/s41522-021-00232-5.
   PubMed Web of Science ®Google Scholar
• He F, Zhang T, Xue K, Fang Z, Jiang G, Huang S, Li K, Gu Z, Shi H, Zhang Z, et al. Fecal multi-omics analysis reveals diverse molecular alterations of gut ecosystem in COVID-19 patients. Anal Chim Acta. 2021;1180:338881. doi:10.1016/j.aca.2021.338881.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wan Y, Zuo T, Yeoh YK, Liu Q, Zhang L, Zhan H, Lu W, Xu W, Lui G, et al. Prolonged impairment of short-chain fatty acid and L-Isoleucine biosynthesis in gut microbiome in patients with COVID-19. Gastroenterology. 2022;162:548–561.e4. doi:10.1053/j.gastro.2021.10.013.
   PubMed Web of Science ®Google Scholar
• Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698–706. doi:10.1136/gutjnl-2020-323020.
   PubMed Web of Science ®Google Scholar
• Sun Z, Song ZG, Liu C, Tan S, Lin S, Zhu J, Dai FH, Gao J, She JL, Mei Z, et al. Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients. BMC Med. 2022;20:24. doi:10.1186/s12916-021-02212-0.
   PubMed Web of Science ®Google Scholar
• Reinold J, Farahpour F, Schoerding AK, Fehring C, Dolff S, Konik M, Korth J, van Baal L, Buer J, Witzke O, et al. The fungal gut microbiome exhibits reduced diversity and increased relative abundance of ascomycota in severe COVID-19 illness and distinct interconnected communities in SARS-CoV-2 positive Patients. Front Cell Infect Microbiol. 2022;12:848650. doi:10.3389/fcimb.2022.848650.
   PubMed Web of Science ®Google Scholar
• Shen Y, Yu F, Zhang D, Zou Q, Xie M, Chen X, Yuan L, Lou B, Xie G, Wang R, et al. Dynamic alterations in the respiratory tract microbiota of patients with COVID-19 and its association with microbiota in the gut. Adv Sci (Weinh). 2022;9:e2200956. doi:10.1002/advs.202200956.
   PubMedGoogle Scholar
• Nashed L, Mani J, Hazrati S, Stern DB, Subramanian P, Mattei L, Bittinger K, Hu W, Levy S, Maxwell GL, et al. Gut microbiota changes are detected in asymptomatic very young children with SARS-CoV-2 infection. Gut. 2022;71:2371–2373. doi:10.1136/gutjnl-2021-326599.
   PubMed Web of Science ®Google Scholar
• Stutz MR, Dylla NP, Pearson SD, Lecompte-Osorio P, Nayak R, Khalid M, Adler E, Boissiere J, Lin H, Leiter W, et al. Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure. Nat Commun. 2022;13:6615. doi:10.1038/s41467-022-34260-2.
   PubMed Web of Science ®Google Scholar
• Moreira-Rosário A, Marques C, Pinheiro H, Araújo JR, Ribeiro P, Rocha R, Mota I, Pestana D, Ribeiro R, Pereira A, et al. Gut microbiota diversity and C-reactive protein are predictors of disease severity in COVID-19 patients. Front Microbiol. 2021;12:705020. doi:10.3389/fmicb.2021.705020.
   PubMed Web of Science ®Google Scholar
• Bernard-Raichon L, Venzon M, Klein J, Axelrad JE, Zhang C, Sullivan AP, Hussey GA, Casanovas-Massana A, Noval MG, Valero-Jimenez AM, et al. Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nat Commun. 2022;13:5926. doi:10.1038/s41467-022-33395-6.
   PubMed Web of Science ®Google Scholar
• Zuo T, Liu Q, Zhang F, Lui GC, Tso EY, Yeoh YK, Chen Z, Boon SS, Chan FK, Chan PK, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021;70:276–284. doi:10.1136/gutjnl-2020-322294.
   PubMed Web of Science ®Google Scholar
• Parker BJ, Wearsch PA, Veloo A, Rodriguez-Palacios A. The genus alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front Immunol. 2020;11:906. doi:10.3389/fimmu.2020.00906.
   PubMed Web of Science ®Google Scholar
• Schult D, Reitmeier S, Koyumdzhieva P, Lahmer T, Middelhoff M, Erber J, Schneider J, Kager J, Frolova M, Horstmann J, et al. Gut bacterial dysbiosis and instability is associated with the onset of complications and mortality in COVID-19. Gut Microbes. 2022;14:2031840. doi:10.1080/19490976.2022.2031840.
   PubMed Web of Science ®Google Scholar
• Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, Guo F, Zhang X, Luo R, Huang C, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020;71:2669–2678. doi:10.1093/cid/ciaa709.
   PubMed Web of Science ®Google Scholar
• Xu R, Lu R, Zhang T, Wu Q, Cai W, Han X, Wan Z, Jin X, Zhang Z, Zhang C. Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults. Commun Biol. 2021;4:240. doi:10.1038/s42003-021-01796-w.
   PubMed Web of Science ®Google Scholar
• Patrier J, Villageois-Tran K, Szychowiak P, Ruckly S, Gschwind R, Wicky PH, Gueye S, Armand-Lefevre L, Marzouk M, Sonneville R, et al. Oropharyngeal and intestinal concentrations of opportunistic pathogens are independently associated with death of SARS-CoV-2 critically ill adults. Crit Care. 2022;26:300. doi:10.1186/s13054-022-04164-0.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gu S, Chen Y, Lu H, Shi D, Guo J, Wu WR, Yang Y, Li Y, Xu KJ, et al. Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut. 2022;71:222–225. doi:10.1136/gutjnl-2021-324090.
   PubMed Web of Science ®Google Scholar
• Liu Q, Mak J, Su Q, Yeoh YK, Lui GC, Ng S, Zhang F, Li A, Lu W, Hui DS, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71:544–552. doi:10.1136/gutjnl-2021-325989.
   PubMed Web of Science ®Google Scholar
• Juthi RT, Sazed SA, Sarmin M, Haque R, Alam MS. COVID-19 and diarrhea: putative mechanisms and management. Int J Infect Dis. 2023;126:125–131. doi:10.1016/j.ijid.2022.11.018.
   PubMed Web of Science ®Google Scholar
• Panpetch W, Somboonna N, Bulan DE, Issara-Amphorn J, Worasilchai N, Finkelman M, Chindamporn A, Palaga T, Tumwasorn S, Leelahavanichkul A. Gastrointestinal colonization of candida albicans increases serum (1→3)-β-D-Glucan, without candidemia, and worsens cecal ligation and puncture sepsis in murine model. Shock. 2018;49:62–70. doi:10.1097/SHK.0000000000000896.
   PubMed Web of Science ®Google Scholar
• Peters BM, Noverr MC, Deepe GS. Candida albicans-Staphylococcus aureus polymicrobial peritonitis modulates host innate immunity. Infect Immun. 2013;81:2178–2189. doi:10.1128/IAI.00265-13.
   PubMed Web of Science ®Google Scholar
• Takesako K, Ikai K, Haruna F, Endo M, Shimanaka K, Sono E, Nakamura T, Kato I, Yamaguchi H. Aureobasidins, new antifungal antibiotics. Taxonomy, fermentation, isolation, and properties. J Antibiot (Tokyo). 1991;44:919–924. doi:10.7164/antibiotics.44.919.
   PubMed Web of Science ®Google Scholar
• Duan X, Tan X, Gu L, Liu J, Hao X, Tao L, Feng H, Cao Y, Shi Z, Duan Y, et al. New secondary metabolites with immunosuppressive activity from the phytopathogenic fungus Bipolaris maydis. Bioorg Chem. 2020;99:103816. doi:10.1016/j.bioorg.2020.103816.
   PubMed Web of Science ®Google Scholar
• Bencsik O, Papp T, Berta M, Zana A, Forgó P, Dombi G, Andersson MA, Salkinoja-Salonen M, Vágvölgyi C, Szekeres A. Ophiobolin a from Bipolaris oryzae perturbs motility and membrane integrities of porcine sperm and induces cell death on mammalian somatic cell lines. Toxins (Basel). 2014;6:2857–2871. doi:10.3390/toxins6092857.
   PubMed Web of Science ®Google Scholar
• Hou H, Chen D, Zhang K, Zhang W, Liu T, Wang S, Dai X, Wang B, Zhong W, Cao H. Gut microbiota-derived short-chain fatty acids and colorectal cancer: ready for clinical translation. Cancer Lett. 2022;526:225–235. doi:10.1016/j.canlet.2021.11.027.
   PubMed Web of Science ®Google Scholar
• Gu C, Mao X, Chen D, Yu B, Yang Q. Isoleucine plays an important role for maintaining immune function. Curr Protein Pept Sci. 2019;20:644–651. doi:10.2174/1389203720666190305163135.
   PubMed Web of Science ®Google Scholar
• Liu Q, Su Q, Zhang F, Tun HM, Mak J, Lui GC, Ng S, Ching J, Li A, Lu W, et al. Multi-kingdom gut microbiota analyses define COVID-19 severity and post-acute COVID-19 syndrome. Nat Commun. 2022;13:6806. doi:10.1038/s41467-022-34535-8.
   PubMed Web of Science ®Google Scholar
• Qin N, Zheng B, Yao J, Guo L, Zuo J, Wu L, Zhou J, Liu L, Guo J, Ni S, et al. Influence of H7N9 virus infection and associated treatment on human gut microbiota. Sci Rep. 2015;5:14771. doi:10.1038/srep14771.
   PubMed Web of Science ®Google Scholar
• Groves HT, Cuthbertson L, James P, Moffatt MF, Cox MJ, Tregoning JS. Respiratory disease following viral lung infection alters the murine gut microbiota. Front Immunol. 2018;9:182. doi:10.3389/fimmu.2018.00182.
   PubMed Web of Science ®Google Scholar
• Harding JN, Siefker D, Vu L, You D, DeVincenzo J, Pierre JF, Cormier SA. Altered gut microbiota in infants is associated with respiratory syncytial virus disease severity. BMC Microbiol. 2020;20:140. doi:10.1186/s12866-020-01816-5.
   PubMed Web of Science ®Google Scholar
• Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. Front Immunol. 2018;9:2640. doi:10.3389/fimmu.2018.02640.
   PubMed Web of Science ®Google Scholar
• Sarkar A, Harty S, Moeller AH, Klein SL, Erdman SE, Friston KJ, Carmody RN. The gut microbiome as a biomarker of differential susceptibility to SARS-CoV-2. Trends Mol Med. 2021;27:1115–1134. doi:10.1016/j.molmed.2021.09.009.
   PubMed Web of Science ®Google Scholar
• Buford TW. (Dis)trust your gut: the gut microbiome in age-related inflammation, health, and disease. Microbiome. 2017;5:80. doi:10.1186/s40168-017-0296-0.
   PubMed Web of Science ®Google Scholar
• Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: a narrative review. Eur J Clin Nutr. 2022;76:489–501. doi:10.1038/s41430-021-00991-6.
   PubMed Web of Science ®Google Scholar
• Miyoshi J, Rao MC, Chang EB. Navigating the human gut microbiome: pathway to success from lessons learned. Gastroenterology. 2020;159:2019–2024. doi:10.1053/j.gastro.2020.09.002.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JVWHO clinical case definition working group on post-COVID-19 conditionA clinical case definition of post-COVID-19 condition by a Delphi consensusLancet Infect Dis202222 e102-102e10710.1016/S1473-3099(21)00703-9
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang F, Shen Y, Zhang X, Cen Y, Wang B, Zhao S, Zhou Y, Hu B, Wang M, et al. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open. 2021;4:e2127403. doi:10.1001/jamanetworkopen.2021.27403.
   PubMed Web of Science ®Google Scholar
• Romero-Duarte Á, Rivera-Izquierdo M, Guerrero-Fernández de Alba I, Pérez-Contreras M, Fernández-Martínez NF, Ruiz-Montero R, Serrano-Ortiz Á, González-Serna RO, Salcedo-Leal I, Jiménez-Mejías E, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. BMC Med. 2021;19:129. doi:10.1186/s12916-021-02003-7.
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Long COVID CollaboratorsWulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, Blyuss O, Bobkova P, Bonsel G, Borzakova S, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604–1615. doi:10.1001/jama.2022.18931.
   PubMed Web of Science ®Google Scholar
• Meringer H, Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. Nat Rev Gastroenterol Hepatol. 2022;19:345–346. doi:10.1038/s41575-022-00611-z.
   PubMed Web of Science ®Google Scholar
• Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, Liu M, Wang Y, Cui D, Wang Y, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10:863–876. doi:10.1016/S2213-2600(22)00126-6.
   PubMed Web of Science ®Google Scholar
• Fernández-de-Las-Peñas C, Rodríguez-Jiménez J, Cancela-Cilleruelo I, Guerrero-Peral A, Martín-Guerrero JD, García-Azorín D, Cornejo-Mazzuchelli A, Hernández-Barrera V, Pellicer-Valero OJ. Post-COVID-19 Symptoms 2 Years After SARS-CoV-2 infection among hospitalized vs nonhospitalized patients. JAMA Netw Open. 2022;5:e2242106. doi:10.1001/jamanetworkopen.2022.42106.
   PubMed Web of Science ®Google Scholar
• Rubin R. SARS-CoV-2 RNA can persist in stool months after respiratory tract clears virus. JAMA. 2022;327:2175. doi:10.1001/jama.2022.7892.
   PubMed Web of Science ®Google Scholar
• Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rössler A, Kimpel J, Adolph TE, Tilg H. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163:495–506.e8. doi:10.1053/j.gastro.2022.04.037.
   PubMed Web of Science ®Google Scholar
• Su Q, Lau RI, Liu Q, Chan F, Ng SC. Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance. Gut. 2022. doi:10.1136/gutjnl-2022-328319.
   Web of Science ®Google Scholar
• Vestad B, Ueland T, Lerum TV, Dahl TB, Holm K, Barratt-Due A, Kåsine T, Dyrhol-Riise AM, Stiksrud B, Tonby K, et al. Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations. J Intern Med. 2022;291:801–812. doi:10.1111/joim.13458.
   PubMed Web of Science ®Google Scholar
• Tian Y, Sun KY, Meng TQ, Ye Z, Guo SM, Li ZM, Xiong CL, Yin Y, Li HG, Zhou LQ. Gut microbiota may not be fully restored in recovered COVID-19 patients after 3-month recovery. Front Nutr. 2021;8:638825. doi:10.3389/fnut.2021.638825.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang J, Zhang D, Ma WL, Wang X. Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. J Microbiol. 2021;59:941–948. doi:10.1007/s12275-021-1206-5.
   PubMed Web of Science ®Google Scholar
• Cui GY, Rao BC, Zeng ZH, Wang XM, Ren T, Wang HY, Luo H, Ren HY, Liu C, Ding SY, et al. Characterization of oral and gut microbiome and plasma metabolomics in COVID-19 patients after 1-year follow-up. Mil Med Res. 2022;9:32. doi:10.1186/s40779-022-00387-y.
   PubMed Web of Science ®Google Scholar
• Penninger JM, Grant MB, Sung J. The role of angiotensin converting enzyme 2 in modulating gut microbiota, intestinal inflammation, and coronavirus infection. Gastroenterology. 2021;160:39–46. doi:10.1053/j.gastro.2020.07.067.
   PubMed Web of Science ®Google Scholar
• Du M, Cai G, Chen F, Christiani DC, Zhang Z, Wang M. Multiomics Evaluation of gastrointestinal and other clinical characteristics of COVID-19. Gastroenterology. 2020;158:2298–2301.e7. doi:10.1053/j.gastro.2020.03.045.
   PubMed Web of Science ®Google Scholar
• Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, Ravelli R, Paul van Schayck J, Mykytyn AZ, Duimel HQ, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369:50–54. doi:10.1126/science.abc1669.
   PubMed Web of Science ®Google Scholar
• Zang R, Gomez Castro MF, McCune BT, Zeng Q, Rothlauf PW, Sonnek NM, Liu Z, Brulois KF, Wang X, Greenberg HB, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020:5. doi:10.1126/sciimmunol.abc3582
   Web of Science ®Google Scholar
• Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14–20. doi:10.1016/j.ejim.2020.04.037.
   PubMed Web of Science ®Google Scholar
• Camargo S, Vuille-Dit-Bille RN, Meier CF, Verrey F. ACE2 and gut amino acid transport. Clin Sci (Lond). 2020;134:2823–2833. doi:10.1042/CS20200477.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, Sigl V, Hanada T, Hanada R, Lipinski S, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487:477–481. doi:10.1038/nature11228.
   PubMed Web of Science ®Google Scholar
• Platten M, Nollen E, Röhrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18:379–401. doi:10.1038/s41573-019-0016-5.
   PubMed Web of Science ®Google Scholar
• Qin WH, Liu CL, Jiang YH, Hu B, Wang HY, Fu J. Gut ACE2 expression, tryptophan deficiency, and inflammatory responses the potential connection that should not be ignored during SARS-CoV-2 infection. Cell Mol Gastroenterol Hepatol. 2021;12:1514–1516.e4. doi:10.1016/j.jcmgh.2021.06.014.
   PubMed Web of Science ®Google Scholar
• Edwinson A, Yang L, Chen J, Grover M. Colonic expression of Ace2, the SARS-CoV-2 entry receptor, is suppressed by commensal human microbiota. Gut Microbes. 2021;13:1984105. doi:10.1080/19490976.2021.1984105.
   PubMed Web of Science ®Google Scholar
• Brown JA, Sanidad KZ, Lucotti S, Lieber CM, Cox RM, Ananthanarayanan A, Basu S, Chen J, Shan M, Amir M, et al. Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection. Gut Microbes. 2022;14:2105609. doi:10.1080/19490976.2022.2105609.
   PubMed Web of Science ®Google Scholar
• Li J, Richards EM, Handberg EM, Pepine CJ, Raizada MK. Butyrate regulates COVID-19-relevant genes in gut epithelial organoids from normotensive rats. Hypertension. 2021;77:e13–13e16. doi:10.1161/HYPERTENSIONAHA.120.16647.
   PubMed Web of Science ®Google Scholar
• Osman IO, Garrec C, de Souza G, Zarubica A, Belhaouari DB, Baudoin JP, Lepidi H, Mege JL, Malissen B, Scola B, et al. Control of CDH1/E-Cadherin gene expression and release of a soluble form of E-Cadherin in SARS-CoV-2 infected Caco-2 intestinal cells: physiopathological consequences for the intestinal forms of COVID-19. Front Cell Infect Microbiol. 2022;12:798767. doi:10.3389/fcimb.2022.798767.
   PubMed Web of Science ®Google Scholar
• Stanifer ML, Kee C, Cortese M, Zumaran CM, Triana S, Mukenhirn M, Kraeusslich HG, Alexandrov T, Bartenschlager R, Boulant S. Critical role of Type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells. Cell Rep. 2020;32:107863. doi:10.1016/j.celrep.2020.107863.
   PubMed Web of Science ®Google Scholar
• Guo Y, Luo R, Wang Y, Deng P, Song T, Zhang M, Wang P, Zhang X, Cui K, Tao T, et al. SARS-CoV-2 induced intestinal responses with a biomimetic human gut-on-chip. Sci Bull (Beijing). 2021;66:783–793. doi:10.1016/j.scib.2020.11.015.
   PubMed Web of Science ®Google Scholar
• Sencio V, Machelart A, Robil C, Benech N, Hoffmann E, Galbert C, Deryuter L, Heumel S, Hantute-Ghesquier A, Flourens A, et al. Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters. Gut Microbes. 2022;14:2018900. doi:10.1080/19490976.2021.2018900.
   PubMed Web of Science ®Google Scholar
• Jiao L, Li H, Xu J, Yang M, Ma C, Li J, Zhao S, Wang H, Yang Y, Yu W, et al. The gastrointestinal tract is an alternative route for SARS-CoV-2 infection in a nonhuman primate model. Gastroenterology. 2021;160:1647–1661. doi:10.1053/j.gastro.2020.12.001.
   PubMed Web of Science ®Google Scholar
• Hoel H, Heggelund L, Reikvam DH, Stiksrud B, Ueland T, Michelsen AE, Otterdal K, Muller KE, Lind A, Muller F, et al. Elevated markers of gut leakage and inflammasome activation in COVID-19 patients with cardiac involvement. J Intern Med. 2021;289:523–531. doi:10.1111/joim.13178.
   PubMed Web of Science ®Google Scholar
• Yonker LM, Gilboa T, Ogata AF, Senussi Y, Lazarovits R, Boribong BP, Bartsch YC, Loiselle M, Rivas MN, Porritt RA, et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest. 2021:131. doi:10.1172/JCI149633
   Web of Science ®Google Scholar
• Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Alimentary Pharmacology & Therapeutics. 2020;51:843–851. doi:10.1111/apt.15731.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Vella A. What to do about the leaky gut. Gut. 2022;71:424–435. doi:10.1136/gutjnl-2021-325428.
   PubMed Web of Science ®Google Scholar
• Kayama H, Okumura R, Takeda K. Interaction between the microbiota, epithelia, and immune cells in the intestine. Annu Rev Immunol. 2020;38:23–48. doi:10.1146/annurev-immunol-070119-115104.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68:1516–1526. doi:10.1136/gutjnl-2019-318427.
   PubMed Web of Science ®Google Scholar
• Matheson NJ, Lehner PJ. How does SARS-CoV-2 cause COVID-19. Science. 2020;369:510–511. doi:10.1126/science.abc6156.
   PubMed Web of Science ®Google Scholar
• Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nat Immunol. 2019;20:1279–1290. doi:10.1038/s41590-019-0451-9.
   PubMed Web of Science ®Google Scholar
• Zhang F, Lau RI, Liu Q, Su Q, Chan F, Ng SC. Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications. Nat Rev Gastroenterol Hepatol. 2022:1–15. doi:10.1038/s41575-022-00698-4.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhang L, Wang Y, Dai T, Qin Z, Zhou F, Zhang L. Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022;7:143. doi:10.1038/s41392-022-00986-0.
   PubMed Web of Science ®Google Scholar
• Viana SD, Nunes S, Reis F. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis. Ageing Res Rev. 2020;62:101123. doi:10.1016/j.arr.2020.101123.
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, Iwasaki A. Microbiota regulates immune defense against respiratory tract influenza a virus infection. Proc Natl Acad Sci U S A. 2011;108:5354–5359. doi:10.1073/pnas.1019378108.
   PubMed Web of Science ®Google Scholar
• Burgueño JF, Abreu MT. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat Rev Gastroenterol Hepatol. 2020;17:263–278. doi:10.1038/s41575-019-0261-4.
   PubMed Web of Science ®Google Scholar
• Monguió-Tortajada M, Franquesa M, Sarrias MR, Borràs FE. Low doses of LPS exacerbate the inflammatory response and trigger death on TLR3-primed human monocytes. Cell Death Dis. 2018;9:499. doi:10.1038/s41419-018-0520-2.
   PubMed Web of Science ®Google Scholar
• Grabauskas G, Gao J, Wu X, Zhou SY, Turgeon DK, Owyang C. Gut microbiota alter visceral pain sensation and inflammation via modulation of synthesis of resolvin D1 in colonic tuft cells. Gastroenterology. 2022. doi:10.1053/j.gastro.2022.07.053.
   Google Scholar
• Legoux F, Salou M, Lantz O. MAIT cell development and functions: the microbial connection. Immunity. 2020;53:710–723. doi:10.1016/j.immuni.2020.09.009.
   PubMed Web of Science ®Google Scholar
• Parrot T, Gorin JB, Ponzetta A, Maleki KT, Kammann T, Emgård J, Perez-Potti A, Sekine T, Rivera-Ballesteros OKarolinska COVID-19 Study Groupet al.MAIT cell activation and dynamics associated with COVID-19 disease severitySci Immunol. 2020;5. doi:10.1126/sciimmunol.abe1670.
   Web of Science ®Google Scholar
• Liu S, Zhao Y, Feng X, Xu H. SARS-CoV-2 infection threatening intestinal health: a review of potential mechanisms and treatment strategies. Crit Rev Food Sci Nutr. 2022:1–19. doi:10.1080/10408398.2022.2103090.
   Web of Science ®Google Scholar
• Shen Z, Xiao Y, Kang L, Ma W, Shi L, Zhang L, Zhou Z, Yang J, Zhong J, Yang D, et al. Genomic diversity of severe acute respiratory syndrome–coronavirus 2 in patients with coronavirus disease 2019. Clin Infect Dis. 2020;71:713–720. doi:10.1093/cid/ciaa203.
   PubMed Web of Science ®Google Scholar
• Pascoal LB, Rodrigues PB, Genaro LM, Gomes A, Toledo-Teixeira DA, Parise PL, Bispo-Dos-Santos K, Simeoni CL, Guimarães PV, Buscaratti LI, et al. Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples. Gut Microbes. 2021;13:1–9. doi:10.1080/19490976.2021.1874740.
   PubMed Web of Science ®Google Scholar
• Chen J, Hall S, Vitetta L. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol. 2021;31:1–13. doi:10.1002/rmv.2211.
   PubMed Web of Science ®Google Scholar
• Liu P, Wang Y, Yang G, Zhang Q, Meng L, Xin Y, Jiang X. The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis. Pharmacol Res. 2021;165:105420. doi:10.1016/j.phrs.2021.105420.
   PubMed Web of Science ®Google Scholar
• Sencio V, Barthelemy A, Tavares LP, Machado MG, Soulard D, Cuinat C, Queiroz-Junior CM, Noordine ML, Salomé-Desnoulez S, Deryuter L, et al. Gut dysbiosis during influenza contributes to pulmonary pneumococcal superinfection through altered short-chain fatty acid production. Cell Rep. 2020;30:2934–2947.e6. doi:10.1016/j.celrep.2020.02.013.
   PubMed Web of Science ®Google Scholar
• Tilg H, Adolph TE, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab. 2022;34:1700–1718. doi:10.1016/j.cmet.2022.09.017.
   PubMed Web of Science ®Google Scholar
• Escarcega RD, Honarpisheh P, Colpo GD, Ahnstedt HW, Couture L, Juneja S, Torres G, Ortiz GJ, Sollome J, Tabor N, et al. Sex differences in global metabolomic profiles of COVID-19 patients. Cell Death Dis. 2022;13:461. doi:10.1038/s41419-022-04861-2.
   PubMed Web of Science ®Google Scholar
• Brevini T, Maes M, Webb GJ, John BV, Fuchs CD, Buescher G, Wang L, Griffiths C, Brown ML, WE S 3rd, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022. 10.1038/s41586-022-05594-0.
   Web of Science ®Google Scholar
• Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018;24:1919–1929. doi:10.1038/s41591-018-0222-4.
   PubMed Web of Science ®Google Scholar
• Liu T, Song X, Khan S, Li Y, Guo Z, Li C, Wang S, Dong W, Liu W, Wang B, et al. The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: an old story, yet mesmerizing. Int J Cancer. 2020;146:1780–1790. doi:10.1002/ijc.32563.
   PubMed Web of Science ®Google Scholar
• Thuy PX, Bao T, Moon EY. Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells. Biomed Pharmacother. 2022;150:113021. doi:10.1016/j.biopha.2022.113021.
   PubMed Web of Science ®Google Scholar
• Chen F, Stappenbeck TS. Microbiome control of innate reactivity. Curr Opin Immunol. 2019;56:107–113. doi:10.1016/j.coi.2018.12.003.
   PubMed Web of Science ®Google Scholar
• Campbell C, McKenney PT, Konstantinovsky D, Isaeva OI, Schizas M, Verter J, Mai C, Jin WB, Guo CJ, Violante S, et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature. 2020;581:475–479. doi:10.1038/s41586-020-2193-0.
   PubMed Web of Science ®Google Scholar
• Ma Y, Luo M, Deng Y, Yang X, Wang X, Chen G, Qin Z, Deng Y, Nan M, Chen Y, et al. Antibiotic-induced primary biles inhibit SARS-CoV-2 endoribonuclease Nsp15 activity in mouse gut. Front Cell Infect Microbiol. 2022;12:896504. doi:10.3389/fcimb.2022.896504.
   PubMed Web of Science ®Google Scholar
• Fu L, Shao S, Feng Y, Ye F, Sun X, Wang Q, Yu F, Wang Q, Huang B, Niu P, et al. Mechanism of microbial metabolite leupeptin in the treatment of COVID-19 by traditional chinese medicine herbs. mBio. 2021;12:e0222021. doi:10.1128/mBio.02220-21.
   PubMed Web of Science ®Google Scholar
• Wei Y, Gao J, Kou Y, Liu M, Meng L, Zheng X, Xu S, Liang M, Sun H, Liu Z, et al. The intestinal microbial metabolite desaminotyrosine is an anti-inflammatory molecule that modulates local and systemic immune homeostasis. Faseb J. 2020;34:16117–16128. doi:10.1096/fj.201902900RR.
   PubMed Web of Science ®Google Scholar
• Steed AL, Christophi GP, Kaiko GE, Sun L, Goodwin VM, Jain U, Esaulova E, Artyomov MN, Morales DJ, Holtzman MJ, et al. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science. 2017;357:498–502. doi:10.1126/science.aam5336.
   PubMed Web of Science ®Google Scholar
• Brogna C, Brogna B, Bisaccia DR, Lauritano F, Marino G, Montano L, Cristoni S, Prisco M, Piscopo M. Could SARS-CoV-2 have bacteriophage behavior or induce the activity of other bacteriophages. Vaccines (Basel). 2022;10:708. doi:10.3390/vaccines10050708.
   PubMed Web of Science ®Google Scholar
• Petrillo M, Brogna C, Cristoni S, Querci M, Piazza O, Van den Eede G. Increase of SARS-CoV-2 RNA load in faecal samples prompts for rethinking of SARS-CoV-2 biology and COVID-19 epidemiology. F1000Res. 2021;10:370. doi:10.12688/f1000research.52540.1.
   PubMedGoogle Scholar
• Petrillo M, Querci M, Brogna C, Ponti J, Cristoni S, Markov PV, Valsesia A, Leoni G, Benedetti A, Wiss T, et al. Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota. F1000Research. 2022;11:292. doi:10.12688/f1000research.109236.1. version 1; peer review: 1 approved with reservations.
   Google Scholar
• Fedele D, De Francesco A, Riso S, Collo A. Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: an overview. Nutrition. 2021;81:111016. doi:10.1016/j.nut.2020.111016.
   PubMed Web of Science ®Google Scholar
• Conte L, Toraldo DM. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis. 2020;14:1753466620937170. doi:10.1177/1753466620937170.
   Web of Science ®Google Scholar
• Ratajczak W, Rył A, Mizerski A, Walczakiewicz K, Sipak O, Laszczyńska M. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim Pol. 2019;66:1–12. doi:10.18388/abp.2018_2648.
   PubMed Web of Science ®Google Scholar
• Merino J, Joshi AD, Nguyen LH, Leeming ER, Mazidi M, Drew DA, Gibson R, Graham MS, Lo CH, Capdevila J, et al. Diet quality and risk and severity of COVID-19: a prospective cohort study. Gut. 2021;70:2096–2104. doi:10.1136/gutjnl-2021-325353.
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Fagoonee S, Rinninella E, Rasetti C, Aquila I, Larussa T, Ricci P, Luzza F, Abenavoli L. Gut microbiota and liver interaction through immune system cross-talk: a comprehensive review at the time of the SARS-CoV-2 pandemic. J Clin Med. 2020;9:2488. doi:10.3390/jcm9082488.
   PubMed Web of Science ®Google Scholar
• He P, Yu L, Tian F, Zhang H, Chen W, Zhai Q. Dietary patterns and gut microbiota: the crucial actors in inflammatory bowel disease. Adv Nutr. 2022;13:1628–1651. doi:10.1093/advances/nmac029.
   PubMed Web of Science ®Google Scholar
• Port JR, Adney DR, Schwarz B, Schulz JE, Sturdevant DE, Smith BJ, Avanzato VA, Holbrook MG, Purushotham JN, Stromberg KA, et al. High-fat high-sugar diet-induced changes in the lipid metabolism are associated with mildly increased COVID-19 severity and delayed recovery in the syrian hamster. Viruses. 2021;13. doi:10.3390/v13122506.
   PubMed Web of Science ®Google Scholar
• Gangitano E, Tozzi R, Gandini O, Watanabe M, Basciani S, Mariani S, Lenzi A, Gnessi L, Lubrano C. Ketogenic diet as a preventive and supportive care for COVID-19 patients. Nutrients. 2021;13:1004. doi:10.3390/nu13031004.
   PubMed Web of Science ®Google Scholar
• Fritsch J, Garces L, Quintero MA, Pignac-Kobinger J, Santander AM, Fernández I, Ban YJ, Kwon D, Phillips MC, Knight K, et al. Low-fat, high-fiber diet reduces markers of inflammation and dysbiosis and improves quality of life in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2021;19:1189–1199.e30. doi:10.1016/j.cgh.2020.05.026.
   PubMed Web of Science ®Google Scholar
• Darand M, Hassanizadeh S, Marzban A, Mirzaei M, Hosseinzadeh M. The association between dairy products and the risk of COVID-19. Eur J Clin Nutr. 2022;76:1583–1589. doi:10.1038/s41430-022-01149-8.
   PubMed Web of Science ®Google Scholar
• Blachier F, Beaumont M, Portune KJ, Steuer N, Lan A, Audebert M, Khodorova N, Andriamihaja M, Airinei G, Benamouzig R, et al. High-protein diets for weight management: interactions with the intestinal microbiota and consequences for gut health. A position paper by the my new gut study group. Clin Nutr. 2019;38:1012–1022. doi:10.1016/j.clnu.2018.09.016.
   PubMed Web of Science ®Google Scholar
• Kim H, Rebholz CM, Hegde S, LaFiura C, Raghavan M, Lloyd JF, Cheng S, Seidelmann SB. Plant-based diets, pescatarian diets and COVID-19 severity: a population-based case-control study in six countries. BMJ Nutr Prev Health. 2021;4:257–266. doi:10.1136/bmjnph-2021-000272.
   PubMedGoogle Scholar
• Bell MG, Ganesh R, Bonnes SL. COVID-19, thegut, and nutritional implications. Curr Nutr Rep. 2023:1–7. doi:10.1007/s13668-023-00465-0.
   PubMedGoogle Scholar
• Perez-Araluce R, Martinez-Gonzalez MA, Fernández-Lázaro CI, Bes-Rastrollo M, Gea A, Carlos S. Mediterranean diet and the risk of COVID-19 in the ‘Seguimiento Universidad de Navarra’ cohort. Clin Nutr. 2022;41:3061–3068. doi:10.1016/j.clnu.2021.04.001.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Cheng L, Zhang R, Liu Y, Wu Z, Zhang X. Tea polyphenols prevent and intervene in COVID-19 through intestinal microbiota. Foods. 2022:11. doi:10.3390/foods11040506.
   PubMedGoogle Scholar
• Zhang Z, Zhang X, Bi K, He Y, Yan W, Yang CS, Zhang J. Potential protective mechanisms of green tea polyphenol EGCG against COVID-19. Trends Food Sci Technol. 2021;114:11–24. doi:10.1016/j.tifs.2021.05.023.
   PubMed Web of Science ®Google Scholar
• Deschasaux-Tanguy M, Srour B, Bourhis L, Arnault N, Druesne-Pecollo N, Esseddik Y, de Edelenyi FS, Allègre J, Allès B, Andreeva VA, et al. Nutritional risk factors for SARS-CoV-2 infection: a prospective study within the NutriNet-Santé cohort. BMC Med. 2021;19(1):290. doi:10.1186/s12916-021-02168-1.
   PubMed Web of Science ®Google Scholar
• Ma W, Nguyen LH, Yue Y, Ding M, Drew DA, Wang K, Merino J, Rich-Edwards JW, Sun Q, Camargo CA, et al. Associations between predicted vitamin D status, vitamin D intake, and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) severity. Am J Clin Nutr. 2022;115:1123–1133. doi:10.1093/ajcn/nqab389.
   PubMed Web of Science ®Google Scholar
• Annweiler C, Beaudenon M, Gautier J, Gonsard J, Boucher S, Chapelet G, Darsonval A, Fougère B, Guérin O, Houvet M, et al. High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): a multicenter, open-label, randomized controlled superiority trial. PLoS Med. 2022;19:e1003999. doi:10.1371/journal.pmed.1003999.
   PubMed Web of Science ®Google Scholar
• Jolliffe DA, Holt H, Greenig M, Talaei M, Perdek N, Pfeffer P, Vivaldi G, Maltby S, Symons J, Barlow NL, et al. Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). BMJ. 2022;378:e071230. doi:10.1136/bmj-2022-071230.
   PubMedGoogle Scholar
• Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran C, Silva C, Franco AS, Macedo MB, Dalmolin H, et al. Effect of a single high dose of vitamin D 3 on hospital length of stay in patients with moderate to severe COVID-19. JAMA. 2021;325:1053–1060. doi:10.1001/jama.2020.26848.
   PubMed Web of Science ®Google Scholar
• Luoto R, Ruuskanen O, Waris M, Kalliomäki M, Salminen S, Isolauri E. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2014;133:405–413. doi:10.1016/j.jaci.2013.08.020.
   PubMed Web of Science ®Google Scholar
• Groeger D, Schiavi E, Grant R, Kurnik-Łucka M, Michalovich D, Williamson R, Beinke S, Kiely B, Akdis CA, Hessel EM, et al. Intranasal Bifidobacterium longum protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection. EBioMedicine. 2020;60:102981. doi:10.1016/j.ebiom.2020.102981.
   PubMed Web of Science ®Google Scholar
• Ji JJ, Sun QM, Nie DY, Wang Q, Zhang H, Qin FF, Wang QS, Lu SF, Pang GM, Lu ZG. Probiotics protect against RSV infection by modulating the microbiota-alveolar-macrophage axis. Acta Pharmacol Sin. 2021;42:1630–1641. doi:10.1038/s41401-020-00573-5.
   PubMed Web of Science ®Google Scholar
• Saleh J, Peyssonnaux C, Singh KK, Edeas M. Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. Mitochondrion. 2020;54:1–7. doi:10.1016/j.mito.2020.06.008.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management. Clin Gastroenterol Hepatol. 2020;18:1663–1672. doi:10.1016/j.cgh.2020.04.001.
   PubMed Web of Science ®Google Scholar
• Bozkurt HS, Ö B. Oral booster probiotic bifidobacteria in SARS-COV-2 patients. Int J Immunopathol Pharmacol. 2021;35:20587384211059677. doi:10.1177/20587384211059677.
   Web of Science ®Google Scholar
• d’Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, Ruberto F, Rossi G, Celani L, Scagnolari C, et al. Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med (Lausanne). 2020;7:389. doi:10.3389/fmed.2020.00389.
   PubMed Web of Science ®Google Scholar
• Ivashkin V, Fomin V, Moiseev S, Brovko M, Maslennikov R, Ulyanin A, Sholomova V, Vasilyeva M, Trush E, Shifrin O, et al. Efficacy of a probiotic consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the treatment of hospitalized patients with COVID-19: a randomized controlled trial. Probiotics Antimicrob Proteins. 2021:1–9. doi:10.1007/s12602-021-09858-5
   PubMed Web of Science ®Google Scholar
• Dauby N. Risks of Saccharomyces boulardii-containing probiotics for the prevention of clostridium difficile infection in the elderly. Gastroenterology. 2017;153:1450–1451. doi:10.1053/j.gastro.2017.04.054.
   PubMed Web of Science ®Google Scholar
• Yelin I, Flett KB, Merakou C, Mehrotra P, Stam J, Snesrud E, Hinkle M, Lesho E, McGann P, McAdam AJ, et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat Med. 2019;25:1728–1732. doi:10.1038/s41591-019-0626-9.
   PubMed Web of Science ®Google Scholar
• Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, et al. Expert consensus document: the international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14:491–502. doi:10.1038/nrgastro.2017.75.
   PubMed Web of Science ®Google Scholar
• Chen D, Wu J, Jin D, Wang B, Cao H. Fecal microbiota transplantation in cancer management: current status and perspectives. Int J Cancer. 2019;145:2021–2031. doi:10.1002/ijc.32003.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang H, Sun Y, Ren Z, Zhu W, Li A, Cui G. Potential associations between microbiome and COVID-19. Front Med (Lausanne). 2021;8:785496. doi:10.3389/fmed.2021.785496.
   PubMed Web of Science ®Google Scholar
• Nejadghaderi SA, Nazemalhosseini-Mojarad E, Asadzadeh Aghdaei H. Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy. Med Hypotheses. 2021;147:110476. doi:10.1016/j.mehy.2020.110476.
   PubMed Web of Science ®Google Scholar
• Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, Iqbal TH, Allegretti JR, Bibbò S, Sokol H, et al. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut. 2020;69:1555–1563. doi:10.1136/gutjnl-2020-321829.
   PubMed Web of Science ®Google Scholar
• Khanna S, Pardi D. Fecal microbiota transplantation for recurrent clostridioides difficile infection: the COVID-19 Era. Am J Gastroenterol. 2020;115:971–974. doi:10.14309/ajg.0000000000000689.
   PubMed Web of Science ®Google Scholar
• Khanna S, Tande A, Rubin DT, Khoruts A, Kahn SA, Pardi DS. Fecal microbiota transplantation for recurrent c difficile infection during the COVID-19 pandemic: experience and recommendations. Mayo Clin Proc. 2021;96:1418–1425. doi:10.1016/j.mayocp.2021.04.005.
   PubMed Web of Science ®Google Scholar
• An X, Zhang Y, Duan L, Jin D, Zhao S, Zhou R, Duan Y, Lian F, Tong X. The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19. Biomed Pharmacother. 2021;137:111267. doi:10.1016/j.biopha.2021.111267.
   PubMed Web of Science ®Google Scholar
• Gajewski A, Kośmider A, Nowacka A, Puk O, Wiciński M. Potential of herbal products in prevention and treatment of COVID-19. Literature review. Biomed Pharmacother. 2021;143:112150. doi:10.1016/j.biopha.2021.112150.
   PubMed Web of Science ®Google Scholar
• Huang F, Li Y, Leung EL, Liu X, Liu K, Wang Q, Lan Y, Li X, Yu H, Cui L, et al. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacol Res. 2020;158:104929. doi:10.1016/j.phrs.2020.104929.
   PubMed Web of Science ®Google Scholar
• Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, Chufang L, Jin Z, Zhenhua J, Haiming J, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156:104761. doi:10.1016/j.phrs.2020.104761.
   PubMed Web of Science ®Google Scholar
• Li LC, Zhang ZH, Zhou WC, Chen J, Jin HQ, Fang HM, Chen Q, Jin YC, Qu J, Kan LD. Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: advances and prospects. Biomed Pharmacother. 2020;130:110641. doi:10.1016/j.biopha.2020.110641.
   PubMed Web of Science ®Google Scholar
• Jan JT, Cheng TR, Juang YP, Ma HH, Wu YT, Yang WB, Cheng CW, Chen X, Chou TH, Shie JJ, et al. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2021:118. doi:10.1073/pnas.2021579118
   Web of Science ®Google Scholar
• Sun Y, Zeng X, Liu Y, Zhan S, Wu Z, Zheng X, Zhang X. Dendrobium officinale polysaccharide attenuates cognitive impairment in circadian rhythm disruption mice model by modulating gut microbiota. Int J Biol Macromol. 2022;217:677–688. doi:10.1016/j.ijbiomac.2022.07.090.
   PubMed Web of Science ®Google Scholar
• Lee D, Li QY, Liu J, Efferth T. Traditional Chinese herbal medicine at the forefront battle against COVID-19: clinical experience and scientific basis. Phytomedicine. 2021;80:153337. doi:10.1016/j.phymed.2020.153337.
   PubMed Web of Science ®Google Scholar
• Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine. 2021;85:153242. doi:10.1016/j.phymed.2020.153242.
   PubMed Web of Science ®Google Scholar